The Director Medical Development, MRD Breast Portfolio, will be responsible for clinical and translational leadership in the development and execution of the company’s precision oncology strategies; including, but not limited to, the design and implementation of next-generation sequencing (NGS) based assays, focused on the development, validation, and regulatory approval of diagnostic tests designed to help determine the most appropriate therapies for breast cancer patients, monitor therapy effectiveness, and detect the presence of residual disease. Include, but are not limited to, the following: Develop the overall vision and strategy for one or more specific Precision Oncology (PO) products, including, but not limited to, the Oncotype DX recurrence score; OncoExTra and therapy selection portfolio; the molecular residual disease (MRD) liquid biopsy portfolio, and digital pathology algorithms, as apply to the clinical care of breast cancer patients, in partnership with internal and cross-functional stakeholders including commercial, product, compliance, market access, and regulatory.